Methods for manipulating phagocytosis mediated by CD47
US-9399682-B2 · Jul 26, 2016 · US
US9624305B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9624305-B2 |
| Application number | US-201615054891-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2016 |
| Priority date | Jan 15, 2008 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
Opening claim text (preview).
What is claimed is: 1. A method of treating a human subject for melanoma, the method comprising: administering to a human subject in need thereof an antibody that disrupts the binding of CD47 with SIRPα, at a dose that achieves a depletion in melanoma cancer cells by increasing phagocytosis of cancer cells. 2. The method of claim 1 , wherein the antibody that disrupts the binding of CD47 with SIRPα specifically binds to CD47. 3. The method of claim 1 , wherein the antibody is a humanized or chimeric monoclonal antibody.
Related publications grouped by family.
Answers are generated from the same data shown on this page.